Table 3.

Showing the Adverse Events Related to Intravitreal Ranibizumab (RBZ) and Bevacizumab (BVZ)

Adverse Events	RBZ + Laser (n = 77)	BVZ + Laser (n = 51)	p-value
Arterial thromboembolic events	0	0	-
Angina pectoris	1 (1.29%)	1 (1.90%)
Pulmonary embolism	0	0
Cerebrovascular accident	0	0
Myocardial infarction	0	0
Hypertension	2 (2.59%)	1 (1.90%)
Non-ocular hemorrhage	0	0
Vitreous hemorrhage	0	1 (1.90)
Retinal detachment	0	0
Endophthalmitis	0	0
Raised IOP	0	1 (1.90)
Ocular pain	3 (3.89%)	3 (5.88%)
Total number of subjects with different kinds of adverse event	6 (7.79%)	7 (13.72%)	0.276
Number of subjects with no adverse events	71 (92.20%)	44 (86.27%)

Notes: Categorical variables in two groups were presented as percentages (%) and compared by the Chi-Square test. In the RBZ + Laser treated group 7.79% of subjects (1.29% angina pectoris, 2.59% hypertension, and 3.89% ocular pain) were found to be associated with different types of adverse events. In the BVZ + Laser treated group, 13.72% of subjects (1.90% angina pectoris, 1.90% hypertension, 1.90% vitreous hemorrhage, IOP raised among 1.90% and 5.88% subject experienced ocular pain) were found to be associated with different types of the adverse event. The rest 92% in RBZ + Laser treated group and 86.27% subjects in BVZ + Laser treated group experienced no adverse events. Subjects with adverse events and subjects without adverse events showed no significant distributional difference (p = 0.276) between the groups. A value of p < 0.05 was considered statistically significant.

Abbreviation: IOP, intraocular pressure.